CAPCOM
29.8.2024 14:01:29 CEST | Business Wire | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that the company will sponsor the Osaka Healthcare Pavilion, which is being exhibited by the Expo 2025, Osaka Pavilion Promotion Committee at Expo 2025, Osaka, Kansai, Japan (Expo 2025, below). Further, the company announced that it will exhibit an interactive experience dubbed Monster Hunter Bridge at the Pavilion in the XD Hall, where visitors can experience the future of entertainment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829488620/en/
Monster Hunter Bridge key art (Graphic: Business Wire)
The theme of the upcoming Expo 2025 is “Designing Future Society for Our Lives.” Inspired by the “REBORN” theme of the Osaka Healthcare Pavilion, Capcom decided to exhibit an interactive attraction that incorporates the concept of nature, living things, and the wonder of life, which are important themes in the Monster Hunter series.
Exhibit Details
Monster Hunter Bridge is a wholly-unique attraction that Capcom created exclusively for Expo 2025. Visitors to the hall will don specialized AR devices and be able to enjoy this interactive attraction that weaves together a 360-degree theater, immersive audio, and vibrating floor. Capcom is developing Monster Hunter Bridge with the aim of blending dreams with reality to provide an immersive experience like never before. The company hopes that visitors look forward to this one-of-a-kind Monster Hunter attraction that will bring them up close with Felyne as well as incredible monster encounters, and can only be experienced at Expo 2025.
Facilities Details
The attraction will be housed in a cylinder-shaped theater within the XD Hall that will measure approximately 12 meters in diameter and 5 meters in height and will be created as part of the Osaka Healthcare Pavilion. Capcom will exhibit Monster Hunter Bridge there by creating a space inside the XD Hall that projects the world of Monster Hunter in 360 degrees, utilizing transparent LED displays on the internal walls and ceiling and projectors on the floor. The company developed new specialized AR devices for visitors that feature 105 degrees of visibility in order to create Expo 2025’s most engaging experience. In addition, the company will enhance the immersion of the space by outfitting it with a multitude of speakers set behind the transparent LED displays, wrapping visitors in 360 degrees of sound while vibrations from the floor are synchronized with the on-screen action.
The company is creating these facilities with the cooperation of partner companies exclusively for Monster Hunter Bridge.
Promotional Ticket Campaign
With the desire to contribute to the development and promotion of Expo 2025, which is being held where Capcom was founded, the company will carry out an Expo 2025 “super-advanced one-day pass” double ticket promotional campaign in which it will give away a total of 80,890 tickets to Expo 2025. The promotion is available to everyone who registers for Capcom ID, a unified account with which users can conveniently manage various Capcom games and web services. The company encourages people to refer to the promotional ticket campaign website for more details.
*Only residents of Japan are eligible to participate in the round one entry period. Please refer to the promotional ticket campaign website regarding eligibility for future campaign entry periods.
Capcom is currently developing Monster Hunter Bridge with the aim of providing a special entertainment experience where dreams and reality become one. The company hopes to create the absolute best content at the event and bring success to the Expo 2025, Osaka Pavilion Promotion Committee.
ABOUT the Monster Hunter series:
The Monster Hunter series consists of hunting action games that pit players against giant monsters in beautiful natural environments. After the series created a social phenomenon through play on handheld consoles and solidified its standing as one of Japan’s most beloved game series, it went on to global-brand status with the release of Monster Hunter: World in 2018. With cumulative sales of the series now exceeding 100 million units, Monster Hunter has grown into a global phenomenon.
[Exhibit Details]
1. Name |
Monster Hunter Bridge |
2. Location |
XD Hall, Osaka Healthcare Pavilion, Expo 2025, Osaka, Kansai |
3. Term |
April 13, 2025 - October 13, 2025 |
4. Admission |
Free* |
5. Official Website |
|
6. Ticket Promotion Website |
|
*Entry to this attraction will be by reservation only. Details will be provided at a later date. |
|
*A separate ticket must be purchased to enter Expo 2025, Osaka, Kansai. |
|
ABOUT CAPCOM
Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829488620/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom